Mckenna Mark C.
SEC-identified person · CIK 1749623 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Apogee Therapeutics, Inc. APGE | Director | filed 2023–2026 |
| Spyre Therapeutics, Inc. SYRE | Director | filed 2024–2026 |
| Helix Acquisition Corp. III HLXC | Director | filed 2026–2026 |
| Newamsterdam Pharma Co N.V. NAMS | Director | filed 2024–2026 |
| Helix Acquisition Corp. II HLXB | Director | filed 2024–2025 |
| Perceptive Capital Solutions Corp PCSC | Director | filed 2024–2024 |
| Prometheus Biosciences, Inc. RXDX | Director · President and CEO | filed 2021–2023 |
| Valeant Pharmaceuticals International, Inc. vrx | President, Salix | filed 2018–2019 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.